Skip to main content

Fund managers raise stake in nearly 300 firms, 10 of them double wealth

 Most of the stocks in which fund managers raised stake in the June quarter are from the small & midcap space belonging to chemical and pharma sectors.

Fund managers were quick to spot the beaten-down stocks and raised stake in as many as 287 companies in the June quarter, data from AceEquity showed as on August 13.

Out of 287, there are 10 companies whose stocks have rallied more than 100 percent so far in 2020. These are Aarti Drugs, Laurus Labs, Granules India, Alkyl Amines, Tata Communications, Navin Fluorine, Birlasoft, Aurobindo Pharma, Vaibhav Global and Neuland Laboratories.

Most of the stocks in which fund managers raised stake in the June quarter are from the small & midcap space. After a sharp sell-off in March, the broader market was first to bounce back to show signs of strength.

Most of the companies which have doubled in 2020 belong to either the chemical sector or companies that manufacture API from the pharma space. Both these sectors are likely to benefit most from the COVID-19 pandemic and the government policies.

 “As market started to stabilise after March, investors – foreign and domestic – found good quality, high growth stocks at affordable valuations. Indian government went into a fire-fighting mode to protect the lives and livelihood of citizens, loan moratoriums were announced,” Tejas Khoday, Co-Founder & CEO, FYERS told Moneycontrol.

“Timely approvals from USFDA, decent sales, scarcity of Active Pharmaceutical Ingredients (APIs) boosted the growth prospects of these companies even as India went into lockdown with stringent conditions,” he said.

Khoday further added that among the top 10 outperformers of the quarter, most were from pharma or chemical-related stocks. Tata Communications, Vaibhav Global, Birlasoft were a value play.


(The above table is for reference only and not buy or sell recommendations)

Analysts also pointed out towards rotation trade happening in the June quarter. Fund managers moved out of largecaps in the financials and consumption space towards growth stocks in the small & midcaps space which are likely to see a big turnaround as economy recovers.

“With a lot of large caps rallying back to pre-COVID levels, and a lot of these stocks in sectors like financials and industrials which could see further stress in the future, or a discretionary consumption drought, Siddharth Panjwani, Chief Strategy Officer Pickright Technologies told Moneycontrol.

“MFs have responded by rotating out of them into the more growth oriented sectors with better prospects as seen in the stocks above,” he said.

Decrease in stake:

There are as many as 363 companies in which fund managers reduced their stake in the June quarter, according to data collated from AceEquity. Out of 363 companies, 4 more than doubles investors' wealth so far in the year 2020.

Stocks which more than doubles investors’ wealth include names like GMM Pfaudler, Mcleod Russel, Astec Lifesciences, and Dixon Technologies. Most of the companies have been hitting a fresh record high in August as well.

While MF buying and selling is a good signal, this information is also dated and might not reflect what the fund manager is doing in real-time, suggest experts. Also, sometimes fund managers adjust the portfolio to manage risk amid high valuations.

“Except for companies belonging to the Chemical and Pharma sector where we can see exponential growth in the medium to long term valuations of most of these stocks looks stretched and it will be advisable to book profits,” Atish Matlawala, Sr Analyst, SSJ Finance & Securities told Moneycontrol.

There are as many as 24 stocks in which fund managers reduced their stake rose more than 50 percent so far in the year 2020 that include names like Amber Enterprises, Essel Propack, Jubilant Lifesciences, Cipla, JB Chemicals, Escorts, Ipca Laboratories, and Alembic Pharma.


(The above table is for reference only and not buy or sell recommendations)

Most of the stocks belong to the chemicals, infra as well as pharma space which have benefitted immensely from the Atmanirbhar schemes, as well as the outbreak of COVID.

Experts are of the view that fund managers preferred to book some profits in some and deployed the cash in those sectors which will bounce back as and when the economy recovers.

“A quick glance of these 364 stocks reveals that the stocks are part of a sectoral move and belong to pharma, agro and specialty chemicals, consumption-related sectors. Atmanirbhar Bharat Abhyan and lockdowns have provided the necessary impetus to many of these stocks,” says Khoday of FYERS.

“As lockdowns end and economy starts opening up fully, companies from other sectors which are undervalued or are fairly valued could get preference. Hence, investors would be interested in booking partial profits or retrieve their initial capital, which could be deployed in value offering stocks,” he said.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com/SD Solutions advises users to check with certified experts before taking any investment decisions.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...